Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Federated Hermes

Federated Hermes MDT Small Cap Growth Fund Institutional Shares (QISGX)

Ticker QISGX · · Holdings as of Jul 31, 2026

Expense ratio
0.89%$89/yr per $10k
5-yr return
+6.5%annualized
1-yr return
+17.1%as of Dec 2025
Net assets
$834.3Mall share classes
Holdings
251

Bottom line

Is QISGX a good fund? The bottom line

QISGX is the Institutional share class of Federated Hermes MDT Small Cap Growth Fund, an actively managed small-cap mutual fund from Federated Hermes.

Its expense ratio is 0.89% — about $89 a year on every $10,000 invested, cheaper than 63% of small-cap funds we track.

It returned +17.1% over one year, +6.5% a year over five years, +11.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $834 million in net assets and 251 holdings, its largest position is Federated Hermes Money Market Obligations Trust (2.0%) and the top 10 make up 14.5% of the portfolio.

What stands out

  • Broadly diversified (251 holdings)
  • No front-end sales load

Updated Nov 19, 2026

What QISGX invests in

The Funds investment objective is to provide long-term capital appreciation.

The Fund seeks to achieve its objective by investing primarily in the common stock of small U.S. companies. The Funds investment advisers (Adviser) investment strategy utilizes a small capitalization (small-cap) growth approach by selecting most of its investments from companies listed in the Russell 2000 Growth Index, an index that measures the performance of those companies with higher price-to-book ratios and higher forecasted growth values within the small-cap segment of the U.S. equity universe, which includes the 2,000 smallest companies by market capitalization within the Russell 3000 Index (an index that includes the 3,000 largest U.S. companies by market capitalization representing approximately 98% of the investable domestic equity market). As of July 31, 2026, companies in the Russell 2000 Growth Index ranged in market capitalization from $31.5 million to $12.7 billion. The…

From the fund's prospectus (filed Sep 28, 2026).

QISGX performance

Fund calendar-year total returns, 2015–2025 2015: +3.5%; 2016: +20.4%; 2017: +25.0%; 2018: −6.2%; 2019: +21.1%; 2020: +29.9%; 2021: +17.6%; 2022: −28.3%; 2023: +19.6%; 2024: +15.6%; 2025: +17.1% +4% 2015 +20% 2016 +25% 2017 −6% 2018 +21% 2019 +30% 2020 +18% 2021 −28% 2022 +20% 2023 +16% 2024 +17% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
QISGX+17.1%+6.5%+11.8%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full QISGX performance history →

What QISGX costs

On a $10,000 investment, QISGX's 0.89% expense ratio costs about $89 a year. The prospectus estimates $1,329 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full QISGX fee table →

QISGX top 10 holdings

#Holding% of fund
1Federated Hermes Money Market Obligations Trust2.01%
2Liquidia Corp LQDA1.68%
3Brightspring Health Services Inc BTSG1.62%
4Zurn Elkay Water Solutions Corp ZWS1.54%
5Indivior Pharmaceuticals Inc INDV1.53%
6Sps Commerce Inc SPSC1.47%
7Acadian Asset Management Inc BSIG1.39%
8Constellium Se CSTM1.17%
9Axsome Therapeutics Inc AXSM1.04%
10Arteris Inc AIP1.04%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 14.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to QISGX

More funds like QISGX →

QISGX FAQ

What is the expense ratio of QISGX?
QISGX's expense ratio is 0.89%, which works out to about $89 a year for every $10,000 invested. The prospectus estimates total costs of $1,329 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is QISGX a good investment?
It depends on your goals, but the data points to: broadly diversified (251 holdings); no front-end sales load. This is general information, not personalized advice.
What does QISGX hold?
QISGX's largest holdings are Federated Hermes Money Market Obligations Trust (2.0%), Liquidia Corp (1.7%), Brightspring Health Services Inc (1.6%), Zurn Elkay Water Solutions Corp (1.5%), Indivior Pharmaceuticals Inc (1.5%). It holds 251 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is QISGX's 5-year return?
QISGX returned +6.5% a year over the five years ending Dec 31, 2025, and +11.8% a year over ten years. Past performance does not guarantee future results.
Does QISGX have a sales load?
No. QISGX has no front-end sales charge.
Who manages QISGX?
QISGX is offered by Federated Hermes through Federated Hermes MDT Series.